Novel CTHRC1 specific antibody and its use
By developing new antibodies that specifically bind to CTHRC1 protein, the problem of existing anti-cancer drugs being toxic to both normal and cancer cells and lacking high-affinity antibodies is solved, and efficient detection of CTHRC1 protein and cancer cell inhibition is achieved, significantly reducing the number of patients with cancer cells. Cancer cells are migrating and invasive, providing effective means for diagnosis and treatment.
Patent Information
- Application Number
- CN202080054185.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-13
- Filing Date
- 2020-06-15
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-06-15
AI Technical Summary
Existing anti-cancer drugs are toxic to both normal and cancer cells and are highly tolerated, making them difficult to effectively target cancer, and the lack of high affinity and specific antibodies against CTHRC1 protein limits its application in diagnosis and treatment.
A novel antibody specifically binding to the CTHRC1 protein has been developed, which is used to diagnose and treat various types of cancers, including pancreatic cancer, breast cancer, ovarian cancer, etc., to inhibit cancer cell migration and invasiveness through high affinity and specific binding. .
The novel antibody can effectively detect trace amounts of CTHRC1, inhibit cancer cell migration and invasiveness, significantly reduce cancer cell migration and invasiveness, provide a pharmaceutical composition for preventing or treating cancer, and is used to diagnose and predict cancer prognosis.
Smart Images

Figure CN114174333B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a novel antibody binding to CTHRC1 and use thereof. Background Art
[0002] Anticancer drugs currently in clinical use can be classified into chemotherapeutics and biotherapeutics. Chemotherapeutics actively developed in the past are drugs that show toxicity to cancer cells, and these drugs have such problems: they are toxic to normal cells and cancer cells and also suffer from tolerance. Therefore, there are restrictions on the development and use of these drugs. Therefore, in recent years, actively developing biotherapeutics that can restore or increase the immune function of the human body and thus weaken the activity of cancer cells as an alternative. The example of the biotherapeutic currently in use or under research and development includes cytokines, recombinant antibodies (for example, monoclonal antibodies), nucleic acid molecule therapeutic agents, angiogenesis inhibitors, etc.
[0003] In biotherapeutic agents, therapeutic monoclonal antibodies are characterized by having low side effects due to their high reaction specificity to targets. Antibodies show therapeutic effects through various mechanisms; for example, they can specifically bind to corresponding antigens to inhibit signal transduction or induce apoptosis by cross-linking, and can additionally show therapeutic effects by activating the immune system in vivo. Therefore, monoclonal antibodies as anticancer agents can specifically track cancer cells and inhibit their activity and induce immune responses and thereby effectively remove cancer cells. Therefore, the treatment using monoclonal antibodies becomes mainstream cancer treatment. In this regard, monoclonal antibodies such as ramucirumab, rituximab, trastuzumab, etc. have been developed and used in the treatment of gastric cancer, breast cancer, liver cancer, etc.
[0004] Meanwhile, collagen triple helix repeat-containing-1 (CTHRC1) is known as a secreted protein involved in vascular remodeling, bone formation, and developmental morphogenesis.
[0005] According to recent studies, it has been reported that CTHRC1 is overexpressed in various types of cancer cells (such as pancreatic cancer, ovarian cancer, breast cancer, melanoma, etc.), and is thus associated with the proliferation or metastasis of cancer. Therefore, these results imply that CTHRC1 plays an important role in invasive tumors. It is also known that CTHRC1 not only induces the proliferation and metastasis of cancer cells, but also stimulates endothelial cells in the tumor microenvironment and thereby participates in angiogenesis (Park et al., Carcinogenesis (2013) 34: 694; Lee et al., Exp Mol Med (2016) 48: e261). As a result of human tumor cDNA array analysis, it was found that CTHRC1 is mainly expressed in human solid tumors, and as a result of transcriptome analysis, it was confirmed that there is an expression difference between lobular breast carcinoma and normal ductal and lobular cells. It was also found that CTHRC1 is expressed in invasive primary melanoma and metastatic melanoma, but not in benign moles or non-invasive samples. In addition, inhibition of CTHRC1 expression reduces the migration of melanoma cell lines in vitro. CTHRC1 was identified in dermatofibrosarcoma protuberans, a localized invasive neoplasm that often metastasizes, but not in skin sarcomas or typical benign fibrous histiocytic tumors. In addition, CTHRC1 expression has been reported to be significantly higher in breast cancer tissue than in normal tissue or precursor lesions and is associated with the risk of bone metastasis. However, there is still a need to develop antibodies that improve binding and affinity to CTHRC1 proteins and have excellent effects in diagnosing and treating various types of cancer. Summary of the invention
[0006] Technical issues
[0007] There is a continuing need to develop antibodies that specifically bind to CTHRC1 for the treatment of various cancers, including refractory cancers. Therefore, the present inventors have developed a novel antibody with high affinity and specificity, and have confirmed that the antibody has anticancer effects in various cancers, thereby completing the present invention.
[0008] Technical Solution
[0009] One object of the present invention is to provide an antibody that specifically binds to collagen triple helix repeat sequence 1 (CTHRC1) protein.
[0010] Another object of the present invention is to provide a polynucleotide encoding the antibody that specifically binds to CTHRC1 protein; an expression vector comprising the polynucleotide; and a host cell comprising the expression vector.
[0011] Still another object of the present invention is to provide a composition and a kit for detecting the antibody specifically binding to CTHRC1 protein.
[0012] Even another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer comprising the antibody.
[0013] Still another object of the present invention is to provide a method for treating cancer using the antibody.
[0014] Still another object of the present invention is to provide a composition comprising the antibody for diagnosing cancer or predicting the prognosis of cancer.
[0015] Still another object of the present invention is to provide a method for providing information for diagnosing cancer, comprising: detecting CTHRC1 protein in a biological sample isolated from a subject suspected of having cancer through an antigen-antibody reaction using the antibody.
[0016] Still another object of the present invention is to provide a method for providing information for predicting cancer prognosis, comprising: using the antibody to detect CTHRC1 protein in a biological sample isolated from a subject suffering from cancer through an antigen-antibody reaction.
[0017] Still another object of the present invention is to provide a kit for diagnosing cancer or predicting the prognosis of cancer, which comprises the composition for diagnosing cancer or predicting the prognosis of cancer.
[0018] Still another object of the present invention is to provide a method for detecting CTHRC1 protein in a sample, which comprises detecting the CTHRC1 antigen-antibody complex using the antibody that specifically binds to the CTHRC1 protein.
[0019] Beneficial Effects
[0020] The novel antibody of the present invention can detect trace amounts of CTHRC1 and can also detect CTHRC1 conjugate vaccines, and thus can be effectively used for quantifying CTHRC1 and CTHRC1 conjugate vaccines. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The results of indirect ELISA of 4H5 and 9E6 mouse antibodies with high binding affinity to CTHRC1 (sensitivity: 4H5, 9E6>>1D1>6C1).
[0022] Figure 2 This is a result that confirmed that 4H5 and 9E6 mouse antibodies have different epitopes, which suggests that they can induce anti-cancer effects through different mechanisms.
[0023] Figure 3This is a result that confirmed that cCMAb45 and cCMAb96 not only have high binding affinity to the CTHRC1 protein, but also bind specifically thereto.
[0024] Figure 4 These results confirm the inhibitory effects of cCMAb45 and cCMAb96 on pancreatic cancer migration in vitro.
[0025] Figure 5 These results confirm the inhibitory effects of cCMAb45 and cCMAb96 on breast cancer migration in vitro.
[0026] Figure 6 These results confirm the inhibitory effects of cCMAb45 and cCMAb96 on ovarian cancer migration in vitro.
[0027] Figure 7 These results confirm the inhibitory effects of cCMAb45 and cCMAb96 on bladder cancer migration in vitro.
[0028] Figure 8 These results confirm the inhibitory effects of cCMAb45 and cCMAb96 on pancreatic cancer invasiveness in vitro.
[0029] Fig. 9 The results confirmed the inhibitory effects of cCMAb45 and cCMAb96 on the invasiveness of patient-derived pancreatic cancer cells in vitro.
[0030] Fig.10 The results confirmed the inhibitory effects of cCMAb45 and cCMAb96 on breast cancer invasiveness in vitro.
[0031] Fig.11 The results confirmed the inhibitory effects of cCMAb45 and cCMAb96 on ovarian cancer invasiveness in vitro.
[0032] Fig.12 These results confirm the inhibitory effects of cCMAb45 and cCMAb96 on bladder cancer invasiveness in vitro.
[0033] Fig.13 is the result of the generation of humanized candidate antibodies 4H5 and 9E6.
[0034] Fig.14 The results are the results of measuring the binding affinity of the 4H5 and 9E6 humanized candidate antibodies.
[0035] Fig.15 The results are the results of validating the efficacy of 4H5 and 9E6 humanized candidate antibodies using the pancreatic cancer cell line Panc-1.
[0036] Fig.16It is the result of re-measuring the binding affinity of the 4H5 and 9E6 humanized candidate antibodies selected as primary antibodies.
[0037] Fig.17 This is the result of revalidation of the efficacy of the top 4H5 and 9E6 humanized antibody candidates.
[0038] Fig.18 These results confirm that hCMAb45 and hCMAb96 specifically bind to the CTHRC1 protein.
[0039] Fig.19 These results confirm the inhibitory effects of hCMAb45 and hCMAb96 on pancreatic cancer migration in vitro.
[0040] Fig. 20 These results confirm the inhibitory effects of hCMAb45 and hCMAb96 on ovarian cancer migration in vitro.
[0041] Fig.21 These results confirm the inhibitory effects of hCMAb45 and hCMAb96 on breast cancer migration in vitro.
[0042] Fig. 22 The results confirmed the inhibitory effects of hCMAb45 and hCMAb96 on the migration of bladder cancer, lung cancer and melanoma in vitro.
[0043] Fig.23 These results confirm the inhibitory effects of hCMAb45 and hCMAb96 on pancreatic cancer invasiveness in vitro.
[0044] Fig.24 The results confirmed the inhibitory effects of hCMAb45 and hCMAb96 on ovarian cancer invasiveness in vitro.
[0045] Fig.25 The results confirm the inhibitory effects of hCMAb45 and hCMAb96 on breast cancer invasiveness in vitro.
[0046] Fig.26 The results confirmed the inhibitory effects of hCMAb45 and hCMAb96 on the invasiveness of bladder cancer, lung cancer and melanoma in vitro.
[0047] Fig. 27 The results confirm the in vivo anticancer effects of hCMAb45 and hCMAb96. The model using the pancreatic cancer cell line BxPC-3 showed a reduced tumor volume compared to the control group. DETAILED DESCRIPTION
[0048] The present invention will be described in detail below. Meanwhile, each description and embodiment disclosed herein can be applied to other descriptions and embodiments respectively. That is, all combinations of various elements disclosed herein fall within the scope of the present application. In addition, the scope of the present invention is not limited by the specific description described below.
[0049] Throughout the disclosure of the present invention, the conventional 1-letter code and 3-letter code for naturally occurring amino acids are used. In addition, the amino acids referred to in the abbreviations according to the present disclosure are described according to the IUPAC-IUB nomenclature.
[0050] Alanine Ala, A Arginine Arg, R
[0051] Asparagine Asn, N Aspartic acid Asp, D
[0052] Cysteine Cys, C Glutamate Glu, E
[0053] Glutamine Gln, Q Glycine Gly, G
[0054] Histidine His, H Isoleucine Ile, I
[0055] Leucine Leu, L Lysine Lys, K
[0056] Methionine Met, M Phenylalanine Phe, F
[0057] Proline Pro, P Serine Ser, S
[0058] Threonine Thr, T Tryptophan Trp, W
[0059] Tyrosine Tyr, Y Valine Val, V
[0060] One aspect of the present invention provides an antibody that specifically binds to collagen triple helix repeat-containing 1 (CTHRC1) protein.
[0061] As used herein, the term "CTHRC1 (collagen triple helix repeat 1)" is a water-soluble protein involved in vascular remodeling, bone formation and morphogenesis, and the protein is known to be expressed in damaged arteries and thereby promote cell migration, and has the function of remodeling damaged aortas by inhibiting collagen synthesis in fibroblasts and smooth muscle cells. It is also known that the expression of CTHRC1 in endothelial cells regulates transforming growth factor-β (TGF-β) and thus inhibits the expression of TGF-β target genes (including collagen). In addition, CTHRC1 transgenic mice increase osteoblastic bone formation, as well as differentiation and mineralization of osteoprogenitor cells, and also interact with Wnt5a to activate the planar cell polarity pathway. Based on these, the role of CTHRC1 in regulating morphogenesis during development can be confirmed.
[0062] The CTHRC1 protein of the present invention can be obtained by recombination through conventional methods or can be purchased commercially. The CTHRC1 of the present invention can be in the form of isolated protein or in the form of binding with other proteins or polysaccharides, and specifically, it can be in the form of binding with bacterial exotoxin, but the form is not limited thereto.
[0063] Antibodies that specifically recognize CTHRC1 proteins can be used to diagnose, prevent or treat diseases that overexpress CTHRC1, such as cancer. In this regard, the present inventors have developed antibodies that bind to human and mouse CTHRC1 proteins with high affinity. The antibodies of the present invention bind to all human CTHRC1 proteins with high affinity and can thus be effectively used in the field of diagnosing diseases that overexpress CTHRC1 proteins, and in the field of preventing or treating cancer.
[0064] As used herein, the term "antibody" refers to a protein molecule that acts as a receptor capable of specifically recognizing an antigen, including immunoglobulin molecules that are immunologically reactive to a specific antigen. The term may include all of polyclonal antibodies, monoclonal antibodies, whole antibodies, and antibody fragments. For the purposes of the present invention, an antibody may be an antibody that specifically binds to a collagen triple helix repeat sequence 1 (CTHRC1) protein. In addition, the term includes chimeric antibodies, humanized antibodies, human antibodies, and divalent or bispecific molecules (e.g., bispecific antibodies), double antibodies, three antibodies, and four antibodies. In addition, the term further includes single-chain antibodies, scab (single-chain antibodies), derivatives of antibody constant regions, and artificial antibodies based on protein scaffolds that have binding functions to neonatal Fc receptors (FcRn). A whole antibody has a structure comprising two full-length light chains and two full-length heavy chains, wherein each light chain is connected to a heavy chain by a disulfide bond. A whole antibody includes IgA, IgD, IgE, IgM, and IgG, wherein IgG includes IgG1, IgG2, IgG3, and IgG4 as subtypes. Antibody fragments refer to fragments having antigen binding function, and include Fd, Fab, Fab', F(ab')2, Fv, etc. Fd refers to the heavy chain portion included in the Fab fragment. Fab has a structure consisting of the variable regions of the light chain and the heavy chain, the constant region of the light chain, and the first constant region (CH1 domain) of the heavy chain, and has one antigen binding site. Fab' differs from Fab in that it has a hinge region containing at least one cysteine residue at the C-terminus of the heavy chain CH1 domain. F(ab')2 antibodies are produced when the cysteine residues in the hinge region of Fab' form a disulfide bond. Variable fragment (Fv) refers to the smallest antibody fragment having only a heavy chain variable region and a light chain variable chain. The disulfide-stabilized Fv (dsFv) antibody fragment is characterized in that the heavy chain variable region and the light chain variable region are linked by a disulfide bond, while the single-chain Fv (scFv) is generally characterized in that the heavy chain variable region and the light chain variable region are linked by a covalent bond through a peptide linker. These antibody fragments can be obtained using proteases (for example, Fab can be obtained by restriction digestion of whole antibodies with papain, and F(ab')2 fragments can be obtained by digestion of whole antibodies with pepsin). Preferably, antibody fragments can be constructed by genetic recombination techniques.
[0065] As used herein, the term "monoclonal antibody" refers to an antibody molecule of single molecular composition obtained from a population of substantially identical antibodies. Such a monoclonal antibody displays a single binding specificity and affinity for a particular epitope.
[0066] In general, immunoglobulins have heavy chains and light chains, and each of the heavy and light chains comprises a constant region and a variable region (these regions are also known as "domains"). The variable regions of the light and heavy chains include three hypervariable regions called complementary determining regions (hereinafter, "CDRs") and four framework regions. The CDRs are primarily responsible for binding to antigenic epitopes. The CDRs of each chain are commonly referred to as CDR1, CDR2, and CDR3 (numbered sequentially from the N-terminus), and are also identified by the chain in which the specific CDR is located.
[0067] As used herein, the term "human antibody" refers to a molecule derived from human immunoglobulin, wherein the full-length amino acid sequence of the antibody (including complementary determining regions and framework regions) is composed of the amino acid sequence of human immunoglobulin. Human antibodies are commonly used to treat human diseases, and may have three or more effective advantages. First, human antibodies can more easily interact with the human immune system so that target cells can be more efficiently lysed by, for example, complement dependent cytotoxicity (CDC) or antibody dependent cell-mediated cytotoxicity (ADCC). Second, there is the advantage that the human immune system does not recognize antibodies as foreign antibodies. Third, there is an advantage that its half-life in the human circulatory system is similar to the half-life of naturally occurring antibodies even when the drug is administered with a smaller amount and at a lower frequency.
[0068] In addition, when the antibody of the present invention comprises a constant region, the antibody may comprise a constant region derived from IgG, IgA, IgD, IgE, IgM, or a combination or hybrid thereof.
[0069] As used herein, the term "combination" means that a polypeptide encoding a single-chain immunoglobulin constant region of the same source is connected to a single-chain polypeptide of a different source to form a dimer or multimer. For example, a dimer or multimer can be formed by two or more constant regions selected from the group consisting of IgG, IgA, IgD, IgE and IgM constant regions.
[0070] As used herein, the term "hybrid" means that the sequences corresponding to two or more immunoglobulin heavy chain constant regions from different sources are present in a single chain of an immunoglobulin heavy chain constant region. For example, a possible hybrid domain can be composed of one to four domains selected from the group consisting of CH1, CH2, CH3 and CH4 of IgG, IgA, IgD, IgE and IgM.
[0071] As used herein, the term "an antibody that specifically binds to collagen triple helix repeat-containing 1 (CTHRC1) protein" refers to an antibody that can inhibit the activity of CTHRC1 protein by binding to the CTHRC1 protein.
[0072] The antibody that specifically binds to CTHRC1 of the present invention is characterized in that it binds to human CTHRC1 protein with high affinity.
[0073] The antibody may comprise (a) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 1 or 11, a heavy chain CDR2 of SEQ ID NO: 2 or 12, and a heavy chain CDR3 of SEQ ID NO: 3 or 13; and (b) a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 4 or 14, a light chain CDR2 of SEQ ID NO: 5 or 15, and a light chain CDR3 of SEQ ID NO: 6 or 16.
[0074] In addition, the antibodies of the present invention may include, but are not limited to, a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 7, 17, 21 or 25; and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 9, 19, 23 or 27.
[0075] In one example of the present invention, the antibody of the present invention having improved affinity and specificity for CTHRC1 protein may specifically comprise a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 2, and a heavy chain CDR3 of SEQ ID NO: 3; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 4, a light chain CDR2 of SEQ ID NO: 5, and a light chain CDR3 of SEQ ID NO: 6; or
[0076] A heavy chain variable region, the heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 11, the heavy chain CDR2 of SEQ ID NO: 12, and the heavy chain CDR3 of SEQ ID NO: 13; and a light chain variable region, the light chain variable region comprising the light chain CDR1 of SEQ ID NO: 14, the light chain CDR2 of SEQ ID NO: 15, and the light chain CDR3 of SEQ ID NO: 16; but not limited thereto.
[0077] In one embodiment of the present invention, the antibody comprising a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO:7 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO:9 is named "4H5" or "cCMAb45", and the antibody comprising a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO:17 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO:19 is named "9E6" or "cCMAb96".
[0078] In addition, the antibody comprising a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO:21 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO:23 was named "4H5" or "hCMAb45", and the antibody comprising a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO:25 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO:27 was named "9E6" or "hCMAb96".
[0079] In one embodiment of the present invention, four novel antibodies 4H5, 9E6, 6C1 and 1D1 having the highest affinity for the antigen are selected by screening B lymphocytes that bind to the CTHRC1 protein, and as a result of confirming the epitopes of 4H5 and 9E6 among the four antibodies, it was confirmed that 4H5 and 9E6 specifically bind to the CTHRC1 protein with high affinity, thereby providing the above two novel antibodies.
[0080] These results indicate that the antibody binding to CTHRC1 protein of the present invention can be effectively used in fields requiring recognition of CTHRC1 protein, such as for diagnosing or treating diseases in which CTHRC1 protein is overexpressed.
[0081] Another aspect of the present invention provides a method for preparing the antibody.
[0082] The antibodies of the present invention can be easily prepared by conventional antibody production techniques. For example, the method for preparing monoclonal antibodies can be performed by using B lymphocytes obtained from immune animals to produce hybridomas (Koeher and Milstein, 1976, Nature, 256: 495) or can be performed using phage display technology, but is not limited thereto. The method for preparing polyclonal antibodies can be easily prepared using conventional antibody production techniques.
[0083] The antibody library using phage display technology is a method of expressing antibodies on the surface of phages with antibody genes directly obtained from B lymphocytes without preparing hybridomas. Many difficulties associated with producing monoclonal antibodies by immortalization of B cells can be overcome by phage display technology. Conventional phage display includes the following steps: 1) inserting oligonucleotides with random sequences into the region corresponding to the N-terminus of phage coat protein pIII (or pIV); 2) expressing a fusion protein consisting of a part of the natural coat protein and a polypeptide encoded by the above oligonucleotides with random sequences; 3) treating a substance that can bind to the polypeptide encoded by the oligonucleotide; 4) eluting the peptide-phage particles bound to the above substances at low pH or using molecules with binding competition; 5) amplifying the eluted phages in the host cells by panning; 6) repeating the above steps to obtain the desired amount of phages; and 7) determining the sequence of the active antibody from the DNA sequence of the phage clones selected by panning.
[0084] The method for preparing the monoclonal antibody of the present invention can be carried out by phage display technology. The technician in the field of the present invention can easily carry out the above steps with reference to the well-known phage display technology, which is disclosed in, for example, Barbas et al. (METHODS: A Companion to Methods in Enzymology 2: 119, 1991 J. Virol. July 2001; 75 (14): 6692-9) and Winter et al. (Ann. Rev. Immunol. 12: 433, 1994). Examples of phages that can be used to construct antibody libraries include, but are not limited to, filamentous phages, such as fd, M13, fl, If1, Ike, Zj / Z, Ff, Xf, Pf1 and Pf3. In addition, examples of vectors that can be used to express heterologous genes on the surface of filamentous phage include, but are not limited to, phage vectors (such as fUSE5, fAFF1, fd-CAT1, or fdtetDOG) or phagemid vectors (such as pHEN1, pComb3, pComb8, or pSEX). In addition, examples of helper phages that can be used to provide natural coat proteins required for successful reinfection of recombinant phage include, but are not limited to, M13K07 or VSCM13.
[0085] The polynucleotides encoding the monoclonal antibody clones of the present invention can be easily separated and sequenced using conventional procedures, for example, by using oligonucleotide primers designed to specifically amplify the heavy chain region and light chain region of interest from phage template DNA. Once the polynucleotides are separated, they can be placed in an expression vector, which is then introduced into a suitable host cell, and the desired monoclonal antibody can be prepared by the transformed host cell (i.e., transformant). Therefore, the method for preparing human monoclonal antibodies can include the step of amplifying the polynucleotides encoding human monoclonal antibodies in an expression vector comprising the polynucleotides encoding human monoclonal antibodies, but is not limited thereto.
[0086] Still another object of the present invention provides a polynucleotide encoding the antibody; an expression vector comprising the polynucleotide; and a host cell introduced with the expression vector.
[0087] The antibodies are as described above.
[0088] The expression vector comprising the polynucleotide encoding the antibody according to the present invention is not particularly limited, but can be a vector capable of replicating and / or expressing the polynucleotide in eukaryotic cells or prokaryotic cells, including mammalian cells (e.g., human, monkey, rabbit, rat, hamster or mouse cells), plant cells, yeast cells, insect cells and bacterial cells (e.g., Escherichia coli). Preferably, it can be a vector comprising at least one selective marker and operably linked to a suitable promoter so that the nucleotide can be expressed in a host cell. For example, the vector can be in the form of introducing the polynucleotide into a phage, plasmid, cosmid, minichromosome, virus or retroviral vector, etc.
[0089] The expression vector comprising a polynucleotide encoding an antibody may be an expression vector comprising each of the polynucleotides encoding the heavy chain or light chain of the antibody or an expression vector comprising all of the polynucleotides encoding the heavy chain or light chain of the antibody.
[0090] The host cell into which the expression vector is introduced may be, but is not particularly limited to, a transformant into which the expression vector is introduced, for example, bacterial cells such as Escherichia coli, Streptomyce, Salmonella typhimurium, etc.; yeast cells; fungal cells such as Pichia pastoris, etc.; insect cells such as Drosophila, Spodoptera, Sf9 cells, etc.; animal cells such as Chinese hamster ovary (CHO) cells, SP2 / 0 (mouse myeloma), human lymphoblastoid cells, COS (monkey kidney fibroblasts), NSO (mouse myeloma), 293T, Bowes melanoma cells, HT-1080, BHK (baby hamster kidney cells), HEK (human embryonic kidney cells), PERC.6 (human retinal cells), etc.; and plant cells.
[0091] As used herein, the term "introducing" refers to delivering a vector comprising a polynucleotide encoding an antibody into a host cell. This introduction can be carried out by various methods known in the art, such as calcium phosphate-DNA coprecipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome-mediated transfection, liposome fusion, lipofection, and protoplast fusion. In addition, transfection means that the desired substance is delivered to the cell by infection using viral particles. In addition, the vector can be introduced into the host cell by gene bombardment, etc. In the present invention, introduction can be used interchangeably with transfection.
[0092] Yet another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the antibody.
[0093] The antibody binds with high affinity to CTHRC1 protein (which is overexpressed in cancer and is known to play an important role in the growth and metastasis of cancer cells), resulting in inhibition, neutralization and / or cytotoxicity of CTHRC1 protein, and thereby preventing or treating diseases in which CTHRC1 protein is overexpressed. The antibody is as described above.
[0094] As used herein, the term "cancer" refers to any type of cancer that can be prevented or treated by the antibodies of the present invention without limitation. Examples may include, but are not limited to, pancreatic cancer, ovarian cancer, breast cancer, melanoma, liver cancer, cervical cancer, gastric cancer, lung cancer, colorectal cancer, oral cancer, and bladder cancer. As used herein, the term "prevention" refers to all actions that inhibit or delay the occurrence of cancer by administering a composition, and the term "treatment" refers to all actions that restore or beneficially change cancer symptoms by administering a composition.
[0095] The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
[0096] As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not cause irritation to an organism and does not eliminate the biological activity and characteristics of the administered compound. Examples of pharmaceutically acceptable carriers that can be used to prepare compositions in the form of liquid solutions include saline solutions, sterile water, Ringer's solution, buffered saline solutions, albumin injection solutions, dextrose solutions, maltodextrin solutions, glycerol, ethanol, and mixtures of one or more thereof. If desired, the composition may also contain other conventional additives, such as antioxidants, buffers, antibacterial agents, etc. In addition, the composition may additionally contain diluents, dispersants, surfactants, adhesives, and lubricants, so that the composition is formulated into injectable preparations, such as aqueous solutions, suspensions, and emulsions, etc., pills, capsules, granules, or tablets.
[0097] Pharmaceutical compositions can be in the form of various oral or parenteral preparations. Pharmaceutical compositions are prepared using conventional diluents or excipients, including fillers, extenders, adhesives, wetting agents, disintegrants, surfactants, etc. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations can be prepared in the following manner: at least one compound is mixed with one or more excipients, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate, talc, etc. can also be used. In addition, liquid preparations for oral administration include suspensions, internal solutions, emulsions and syrups, etc. In addition to water (commonly used as a simple diluent) and liquid paraffin, various excipients can be included, for example, wetting agents, sweeteners, flavoring agents, preservatives, etc. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilizers, suppositories, etc. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. can be used as non-aqueous solvents and suspending agents. Bases for suppositories can include witepsol, polyethylene glycol, Tween 61, cocoa butter, laurel fat, glycerinated gelatin, etc.
[0098] The pharmaceutical composition may have any one formulation selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solutions, lyophilized agents, and suppositories.
[0099] The composition of the present invention may be administered in a pharmaceutically effective amount.
[0100] As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to any medical treatment. The effective dose level of the composition can be determined according to the following: subject type, disease severity, subject age and gender, cancer type, drug activity, drug sensitivity, administration time, administration route, excretion rate, treatment duration, factors including drugs used in combination with the composition, and other factors known in the medical field. The composition of the present invention can be administered alone or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. In addition, the composition can be administered in a single dosage form or multiple dosage forms. Importantly, in view of all the above factors, the composition is administered in the minimum amount that can show the maximum effect without causing side effects, and the minimum amount can be easily determined by those skilled in the art.
[0101] Even another aspect of the invention provides a method for treating cancer using the antibodies.
[0102] The antibodies and cancers are as described above.
[0103] The method for treating cancer can be a method for treating cancer comprising the following steps: administering a pharmaceutical composition comprising an antibody and a pharmaceutically acceptable carrier to a subject suffering from cancer or suspected of suffering from cancer. In this article, the pharmaceutically acceptable carrier is as described above. The method for treating cancer can specifically be a method for treating cancer comprising the following steps: administering a composition comprising an antibody to a subject suffering from cancer.
[0104] Examples of subjects include mammals, including cows, pigs, sheep, chickens, dogs, humans, etc., and birds. The subject may be any subject in which cancer is to be treated by administering the composition of the present invention.
[0105] In particular, the composition can be administered in a single dose or multiple doses in a pharmaceutically effective amount. In this article, the composition can be administered in the form of a liquid, powder, aerosol, capsule, enteric coated tablet or capsule, or suppository. In addition, the composition can be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, intranasally, intrapulmonaryly or intrarectally, but is not limited thereto. However, when the composition is administered orally, the peptide is digested in the stomach, and for this reason, the oral composition should be formulated so that the active ingredient is coated or protected from decomposition in the stomach. In addition, the pharmaceutical composition can be administered using any device capable of delivering the active ingredient to the target cell.
[0106] Another aspect of the present invention provides a method for providing information for diagnosing cancer, comprising detecting CTHRC1 protein in a biological sample isolated from a subject suspected of having cancer by antigen-antibody reaction using the antibody. In addition, the method may be a method for diagnosing cancer.
[0107] Still further another aspect of the present invention provides a method for providing information for predicting cancer prognosis, comprising using the antibody to detect the CTHRC1 protein in a biological sample separated from a subject suffering from cancer by antigen-antibody reaction. In addition, the method can be a method for predicting cancer prognosis. The antibody, cancer, subject and CTHRC1 protein are as described above. Because it is known that CTHRC1 protein is overexpressed in various cancers, the antibody of the present invention can be effectively used to diagnose cancers known to overexpress CTHRC1 protein. In addition, it has also been reported that overexpression of CTHRC1 protein induces epithelial-mesenchymal transition (EMT) associated with metastasis and is thus associated with poor cancer prognosis. Therefore, the antibody according to the present invention can be effectively used to predict cancer prognosis.
[0108] The method for providing information for diagnosing cancer or predicting the prognosis of cancer can achieve the detection of CTHRC1 protein by reacting the human monoclonal antibody specific to CTHRC1 of the present invention with a biological sample isolated from a subject suspected of having or suffering from cancer, and detecting the formation of an antigen-antibody complex, thereby providing information for diagnosing cancer or predicting the prognosis of cancer.
[0109] Specifically, the method may be a method for providing information for diagnosing cancer or a method for diagnosing cancer comprising the following steps: (a) treating a biological sample separated from a subject suspected of having cancer with an antibody to detect CTHRC1 protein by antigen-antibody reaction; and (b) comparing the level of CTHRC1 protein detected in step (a) with the level in a control group, and if the level of CTHRC1 protein in the biological sample is higher than the level in the control group, judging the subject to be a cancer patient.
[0110] Specifically, the method may be a method for providing information for predicting cancer prognosis or a method for predicting cancer prognosis comprising the following steps: (a) treating a biological sample isolated from a subject suffering from cancer with an antibody to detect CTHRC1 protein through an antigen-antibody reaction; and (b) comparing the level of CTHRC1 protein detected in step (a) with the level in a control group.
[0111] As used herein, the term "biological sample" is intended to include, but not limited to, tissues, cells, whole blood, serum, plasma, tissue dissection samples (brain, skin, lymph node, spinal cord, etc.), cell culture supernatant, disrupted eukaryotic cells, and bacterial expression systems, etc. These biological samples can be reacted with antibodies in a manipulated or non-manipulated state to determine the presence of CTHRC1 protein or the presence or absence of cancer.
[0112] As used herein, the term "antigen-antibody complex" refers to a conjugate between the CTHRC1 protein antigen in a sample and the monoclonal antibody of the present invention that recognizes the CTHRC1 protein antigen. The formation of such an antigen-antibody complex can be detected by any method selected from the group consisting of: colorimetry, electrochemical method, fluorescence method, luminescence method, particle counting method, visual evaluation and scintillation counting method, but is not limited thereto, and various methods can be used.
[0113] In the present invention, various labels can be used to detect antigen-antibody complexes. Specific examples of labels include, but are not limited to, enzymes, fluorescent materials, ligands, luminescent materials, microparticles, and radioisotopes.
[0114] Examples of enzymes that can be used as detection labels include acetylcholinesterase, alkaline phosphatase, βD-galactosidase, horseradish peroxidase, β-lactamase, etc. Examples of fluorescent materials include fluorescein, Eu 3+ 、Eu 3+ Chelate, cryptate, etc. Examples of ligands include biotin derivatives, etc., and examples of luminescent materials include acridinium esters, isoluminol derivatives, etc. In addition, examples of microparticles include colloidal gold, colored latex, etc., and examples of radioactive isotopes include 57 Co. 3 H. 125 I and 125 I-Bonton Hunter reagent, etc.
[0115] Preferably, the antigen-antibody complex can be detected by enzyme-linked immunosorbent assay (ELISA). Examples of ELISA include various ELISAs, such as direct ELISA, which uses a labeled antibody that recognizes an antigen attached to a solid support; indirect ELISA, which uses a labeled secondary antibody that recognizes a capture antibody in an antibody complex, and the capture antibody recognizes an antigen attached to a solid support; direct sandwich ELISA, which uses another labeled antibody that recognizes an antigen in an antigen-antibody complex attached to a solid support; indirect sandwich ELISA, which involves reacting an antigen with another antibody in an antigen-antibody complex attached to a solid support and using a labeled secondary antibody that recognizes another antibody; and competitive ELISA, which involves competition between different antigens having the same antibody binding site; and the like.
[0116] The monoclonal antibody may have a detectable label. If the monoclonal antibody does not have a detectable label, it can be captured and detected by treating it with another antibody that has a detectable label.
[0117] Still another aspect of the present invention provides a composition for diagnosing cancer or predicting the prognosis of cancer.
[0118] The antibody and cancer are the same as described above. By using the composition for diagnosing cancer or predicting cancer prognosis comprising the antibody specific to CTHRC1 protein of the present invention, a disease (such as cancer) associated with the expression or expression level of CTHRC1 protein can be diagnosed, or cancer prognosis can be predicted.
[0119] Still another aspect of the present invention provides a kit for diagnosing cancer or predicting the prognosis of cancer, comprising the composition for diagnosing cancer or predicting the prognosis of cancer.
[0120] The composition and cancer are the same as described above. In addition, the kit for diagnosing cancer may further include a composition, solution or device having one or more other components suitable for the assay method.
[0121] Still another aspect of the present invention provides a composition and a kit for detecting CTHRC1 protein, wherein the composition and the kit comprise an antibody that specifically binds to collagen triple helix repeat-containing sequence 1 (CTHRC1) protein.
[0122] Still another aspect of the present invention provides a method for detecting CTHRC1 protein in a sample, which comprises detecting the CTHRC1 antigen-antibody complex using the antibody that specifically binds to CTHRC1. The detection method can be used to quantify conjugate vaccines.
[0123] As used herein, the term "antigen-antibody complex" refers to a conjugate between a relevant antigen in a sample and an antibody that recognizes the antigen. The detection of the antigen-antibody complex can be carried out using any method well known in the art, such as spectroscopy, photochemistry, biochemistry, immunochemistry, electrical methods, absorption spectroscopy, chemical methods and other methods. Specifically, it can be detected by any method selected from the group consisting of: colorimetry, electrochemistry, fluorescence, luminescence, particle counting, visual assessment and scintillation counting, as well as protein blotting, ELISA, radioimmunoassay, radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, flow cytometry (FACS), protein chip method, etc., but the method is not limited thereto.
[0124] In the present invention, various labels can be used to detect antigen-antibody complexes. Specific examples of labels include, but are not limited to, enzymes, fluorescent materials, ligands, luminescent materials, microparticles, and radioisotopes.
[0125] Examples of enzymes that can be used as detection labels include acetylcholinesterase, alkaline phosphatase, βD-galactosidase, horseradish peroxidase, β-lactamase, etc. Examples of fluorescent materials include fluorescein, Eu 3+ 、Eu 3+ Chelate, cryptate, etc. Examples of ligands include biotin derivatives, etc., and examples of luminescent materials include acridinium esters, isoluminol derivatives, etc. In addition, examples of microparticles include colloidal gold, colored latex, etc., and examples of radioactive isotopes include 57 Co. 3 H. 125 I and 125 I-Barton Hunt reagent, etc. These materials are not limited thereto.
[0126] The kit of the present invention may be in the form of an enzyme-linked immunosorbent assay (ELISA) kit. Specifically, the kit may include the above-mentioned antibody as a capture antibody, and the ELISA may include (i) a polyclonal antibody that binds to CTHRC1; (ii) a capture antibody in the form of an antibody that specifically binds to collagen triple helix repeat 1 (CTHRC1) protein; and (iii) an antibody that binds to a detection marker IgG Fc; but is not limited thereto.
[0127] As used herein, the term "enzyme-linked immunosorbent assay (ELISA)" is also referred to as enzyme immunoassay, and is a method for quantitative determination using absorbance via the reaction of an enzyme with a substrate by binding an enzyme to an antibody for forming an antigen-antibody complex. Examples of ELISA include various ELISAs, such as direct ELISA, which uses a labeled antibody that recognizes an antigen attached to a solid support; indirect ELISA, which uses a labeled secondary antibody that recognizes a capture antibody in an antibody complex, the capture antibody recognizing an antigen attached to a solid support; direct sandwich ELISA, which uses another labeled antibody that recognizes an antigen in an antigen-antibody complex attached to a solid support; indirect sandwich ELISA, which involves reacting an antigen with another antibody in an antigen-antibody complex attached to a solid support and using a labeled secondary antibody that recognizes another antibody; and competitive ELISA, which involves competition between different antigens having the same antibody binding site; and the like.
[0128] Very trace amounts of CTHRC1 protein can be detected using: an antibody of the present invention that specifically binds to CTHRC1 protein; a composition for detection comprising the antibody; a kit; and a method for detecting CTHRC1 protein using the antibody. The amount of protein to be detected can be specifically less than 1 mg, less than 100 μg, and more specifically less than 10 μg, less than 1 μg, less than 100 ng, less than 10 ng, and less than 1 ng.
[0129] In one embodiment of the present invention, it was confirmed that CTHRC1 protein at a level of several ng can be detected by indirect ELISA using 4H5 and 9E6 antibodies that specifically bind to CTHRC1 as capture antibodies, and the conjugate vaccine can also be detected by ELISA.
[0130] As described above, a very small amount of CTHRC1 protein can be detected by using the antibody of the present invention compared to conventional kits for detecting CTHRC1 protein. Therefore, the antibody of the present invention can be effectively used for quantifying CTHRC1 protein and vaccines using the protein.
[0131] [Mode for Carrying Out the Invention]
[0132] Hereinafter, the present invention will be described in more detail by examples and experimental examples. However, these examples and experimental examples are given for illustrative purposes only, and the scope of the present invention is not intended to be limited to or by these examples and experimental examples.
[0133] <Example 1: Mouse Antibodies cCMAb45 and cCMAb96>
[0134] Example 1-1: Discovery of 4H5 and 9E6
[0135] In order to develop antibodies targeting CTHRC1 protein, mouse monoclonal antibodies that bind to CTHRC1 protein were found. Specifically, once antibodies against CTHRC1 protein were produced by injecting CTHRC1 protein into mice, B lymphocytes were separated from the spleen of mice. The separated lymphocytes were diluted so that only one B lymphocyte was allowed to enter each well of a 96-well plate coated with CTHRC1 protein. Then, B lymphocytes that bind to CTHRC1 protein were screened using horseradish peroxidase (HRP) labeled anti-mouse antibodies.
[0136] As a result, four anti-CTHRC1 mouse monoclonal antibodies (4H5, 9E6, 6C1, and 1D1) were discovered.
[0137] Example 1-2: Confirmation of affinity for CTHRC1
[0138] Indirect ELISA was performed to identify the antibody having the highest affinity to CTHRC1 protein among the four anti-CTHRC1 mouse monoclonal antibodies found in Example 1-1.
[0139] The immunoplate coated with CTHRC1-Fc and CTHRC1-His was treated with four antibodies (4H5, 9E6, 6C1 and 1D1) at different concentrations and reacted for 2 hours, and OD (optical density) values were measured using HRP-labeled anti-mouse antibodies as secondary antibodies. In particular, higher OD values indicated that the antibodies bound CTHRC1 with higher affinity.
[0140] As a result, it was confirmed that although the OD values of all four antibodies increased according to the concentration of CTHRC1 protein, two antibodies (4H5 and 9E6) bound to CTHRC1 protein with higher affinity than the other antibodies ( Figure 1 ).
[0141] Example 1-3: Confirmation of epitope
[0142] In order to confirm the epitopes of 4H5 and 9E6 with high affinity among the four anti-CTHRC1 mouse antibodies, competitive ELISA was performed. In particular, epitope refers to a position of an antigen recognized by an antibody.
[0143] The immunoplate was coated with CTHRC1 protein, and then biotin-labeled 4H5 and 9E6 antibodies and unlabeled antibodies were added thereto at a ratio of 1:0, 1:3, 1:6, 1:12.5, 1:25, 1:50 and 1:100. Streptavidin-HRP was used as a secondary antibody to measure the OD value of each antibody. In particular, when the two antibodies (4H5 and 9E6) had the same epitope, the OD value decreased as the concentration of the unlabeled antibody increased, and when the epitopes of the two antibodies were different from each other, the OD value did not change even when the concentration of the unlabeled antibody was increased.
[0144] As a result, it was confirmed that 4H5 and 9E6 have different epitopes from each other ( Figure 2 ).
[0145] Example 1-4: Preparation of chimeric antibodies cCMAb45 and cCMAb96
[0146] In order to minimize the immunogenicity of 4H5 and 9E6 mouse antibodies that are specific for CTHRC1 and have high affinity, chimeric antibodies were prepared in which the variable regions of the mouse antibodies were retained and only their constant regions were replaced with human-derived proteins. The resulting antibodies were named cCMAb45 and cCMAb96.
[0147] Example 1-5: Affinity analysis (indirect ELISA)
[0148] The affinity of cCMAb45 and cCMAb96, anti-CTHRC1 chimeric antibodies prepared in Examples 1 to 3, to CTHRC1 protein was verified. Indirect ELISA was performed to test the affinity of antigen and antibody.
[0149] 100 μ L CTHRC1 is distributed on the immunoplate with a concentration of 5 μ g / mL and coated overnight at 4 ° C. The next day, the coated CTHRC1 solution is abandoned and blocked for 2 hours. Thereafter, cCMAb45 and cCMAb96 antibodies are treated with different concentrations and reacted at room temperature for 2 hours, and the antibodies are abandoned to remove unbound antibodies, and then the plates are washed. Anti-human Fc-HRP is used as a second antibody to identify human constant regions to measure OD values. In particular, higher OD values indicate higher affinity between CTHRC1 and antibodies.
[0150] As a result, cCMAb45 showed a 5.2×10 -10 M of K D value, and cCMAb96 showed 4.3×10 -10 M of K D It was confirmed that the two antibodies showed very high affinity for CTHRC1 protein ( Figure 3 ).
[0151] Example 1-6: Specificity analysis (indirect ELISA)
[0152] Indirect ELISA was performed to confirm whether cCMAb45 and cCMAb96 specifically bind to CTHRC1. As in affinity analysis, the immunoplate was coated with CTHRC1 protein and a variety of nonspecific antigenic proteins. The next day, the coating solution was discarded and blocked, and cCMAb45 and cCMAb96 were added thereto at a concentration of 0 μg / mL, 1 μg / mL and 5 μg / mL, and reacted for 2 hours. Thereafter, the solution containing the antibody was discarded and washed to remove unbound antibodies. Anti-human kappa light chain-HRP was used as a secondary antibody to measure OD values.
[0153] As a result, it was confirmed that cCMAb45 and cCMAb96 showed high specificity for CTHRC1 ( Figure 3 ).
[0154] Example 1-7: Confirmation of the inhibitory effect on cancer cell migration
[0155] To validate the therapeutic efficacy of cCMAb45 and cCMAb96, the inhibitory effect on migration was confirmed using pancreatic, breast, ovarian, and bladder cancer cell lines.
[0156] Specifically, cCMAb45 and cCMAb96 are prepared at a concentration of 1 μg / mL and 5 μg / mL or 1 μg / mL and 10 μg / mL, diluted in serum-free medium together with the cell line, and distributed in the upper chamber of Transwell. The culture medium containing serum is placed in the lower chamber to produce an environment in which cells can migrate. The number of migrating cells is measured by culturing the antibody in each cell line for an appropriate time.
[0157] As a result, it was confirmed that the degree of migration of cancer cells was significantly reduced in the groups treated with cCMAb45 and cCMAb96 compared with the control IgG group ( Figures 4 to 7 ).
[0158] Example 1-8: Confirmation of the inhibitory effect on cancer cell invasion
[0159] In order to verify the efficacy of cCMAb45 and cCMAb96, the inhibitory effect on cancer cell invasiveness was confirmed in the same manner as in Examples 1 to 7. The experiment was performed using pancreatic cancer, patient-derived pancreatic cancer cell lines, breast cancer, ovarian cancer, and bladder cancer.
[0160] The upper chamber of Transwell is coated with Matrigel that can artificially simulate extracellular matrix, and the invasive ability of cancer cells is observed. cCMAb45 and cCMAb96 are prepared with the concentration of 1 μ g / mL and 5 μ g / mL or 1 μ g / mL and 10 μ g / mL, diluted in serum-free medium together with cell line, and assigned to the upper chamber of Transwell. The culture medium containing serum is placed in the lower chamber. After antibody is cultivated for a certain period of time, the number of cells migrated by invading Matrigel is measured.
[0161] As a result, it was confirmed that the invasive ability of cancer cells was reduced in the groups treated with cCMAb45 and cCMAb96 compared with the control IgG group ( Figures 8 to 12 ).
[0162] <Example 2: Humanized hCMAb45 and hCMAb96 Antibodies>
[0163] Example 2-1: Construction of humanized antibody library
[0164] In order to reduce the immunogenicity of cCMAb45 and cCMAb96 as anti-CTHRC1 chimeric antibodies, humanized antibodies were prepared in which the framework regions (hereinafter referred to as "FR") maintaining the CDR regions were replaced with human framework regions except for the CDR regions which are the most important parts for antigen binding.
[0165] A humanized antibody library having various FR regions including the CDR regions of cCMAb45 and cCMAb96 was constructed using CDR grafting technology.
[0166] Example 2-2: Selection of humanized antibodies and IgG conversion
[0167] From the humanized antibody library constructed above, clones that were specific for CTHRC1 and had high affinity were selected. IgG transient expression tests were performed on HEK293F cells to purify each of the eight antibodies against 4H5 and 9E6, and the purity was confirmed by SDS-PAGE.
[0168] As a result, the production of 4H5 humanized antibody was measured to be 15 mg / L to 67.3 mg / L, and the production of 9E6 humanized antibody was measured to be 3.1 mg / L to 33.3 mg / L ( Fig.13 ).
[0169] Example 2-3: Analysis of affinity of humanized antibodies
[0170] The eight candidate clones of 4H5 prepared in Example 2-2 were subjected to indirect ELISA to analyze affinity. The immunoplate was coated with CTHRC1-His, and the next day, the concentrations of the eight humanized candidate antibodies and cCMAb45 were gradually diluted by 1 / 3 from the maximum concentration of 500 ng / mL and added to the plate. Anti-human Fc-HRP was used as the secondary antibody to measure the OD value. Affinity was expressed as K D Value. Low K D Values indicate high affinity.
[0171] As a result, the K D The K values were measured for cCMAb45. D Similar or lower value.
[0172] As a result of analyzing eight candidate clones of the 9E6 humanized antibody in the same manner as above, the K D The K values were measured as those of cCMAb96. D The value is similar or slightly higher.
[0173] Specifically, the affinity of the 4H5 humanized antibody was measured to be 0.82×10 -10 M to 2.5×10 -10 M, and the affinity of the 9E6 humanized antibody was measured to be 1.61 × 10 -10 M to 4.8×10 -10 M( Fig.14 ).
[0174] Example 2-4: Efficacy testing of humanized antibodies
[0175] To test the efficacy of candidate clones of 4H5 and 9E6 humanized antibodies, migration assays were performed using the pancreatic cancer cell line Panc-1. 5 μg / mL of each antibody and 5 × 10 4The cells were diluted with serum-free medium and distributed in the upper chamber of the Transwell. Then, the medium containing serum was placed in the lower chamber to create an environment in which the cells can migrate. The number of migrated cells was measured by culturing the antibody for 24 hours, and the efficacy of the candidate antibody was evaluated.
[0176] As a result, it was confirmed that the degree of migration of cancer cells was significantly reduced in the groups treated with cCMAb45 and cCMAb96 compared with the control IgG ( Figures 4 to 7 ).
[0177] The result was that the candidate clones of the 4H5 humanized antibody reduced the cell migration ability by 30% to 50% compared to the control IgG, and the candidate clones of the 9E6 humanized antibody reduced the cell migration ability by 30% to 40%. In summary, it was confirmed that all candidates of the 4H5 and 9E6 humanized antibodies had similar or higher efficacy than cCMAb45 and cCMAb96 ( Fig.15 ).
[0178] Example 2-5: Selection of humanized antibodies and re-evaluation of affinity and efficacy
[0179] Antibodies were selected by evaluating candidate clones for 4H5 and 9E6 humanized antibodies based on the following three criteria: affinity, efficacy, and yield. SA2759, SA2761, SA2762, and SA2765 were selected for the 4H5 humanized antibody, and SA2768, SA2769, and SA2770 were selected for the 9E6 humanized antibody.
[0180] To re-evaluate the affinity and efficacy of the antibodies selected based on the above criteria, indirect ELISA was used to evaluate affinity, and migration assay was used to assess efficacy. The experimental methods were the same as described in Examples 2-3 and 2-4.
[0181] The results are that, regarding affinity, it is confirmed that K D The K values were measured for cCMAb45 and cCMAb96. D The values were similar to or lower than those of the first measurement, which was similar to the first measurement, and also reduced the cell migration ability by 30% to 50%. Specifically, it was confirmed that the selected 4H5 humanized antibody had an affinity of several pM and reduced the cell migration ability by 40%, and the 9E6 humanized antibody had an affinity of tens of pM and reduced the cell migration ability by 50% ( Fig.16 and 17 ).
[0182] Finally, SA2765 was named hCMAb45, and SA2770 was named hCMAb96.
[0183] Example 2-6: Analysis of the specificity of hCMAb45 and hCMAb96
[0184] Indirect ELISA was performed to determine whether hCMAb45 and hCMAb96 specifically bind to CTHRC1. Immunoplates were coated with CTHRC1-His and a variety of nonspecific antigens. The next day, hCMAb45 and hCMAb96 were reacted with antigen at concentrations of 0 μg / mL, 1 μg / mL, and 5 μg / mL, and then anti-human kappa light chain-HRP was used as a secondary antibody to measure OD values.
[0185] As a result, it was confirmed that hCMAb45 and hCMAb96 specifically bound to CTHRC1 ( Fig.18 ).
[0186] Example 2-7: Confirmation of the inhibitory effect on cancer cell migration
[0187] To verify the therapeutic efficacy of hCMAb45 and hCMAb96, the inhibitory effect on cancer cell migration was confirmed. Pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, lung cancer and malignant melanoma were used, and the experimental method was the same as that described in Examples 1-7.
[0188] As a result, it was confirmed that the migration ability of cancer cells was significantly reduced in the groups treated with hCMAb45 and hCMAb96 compared with the control IgG ( Figures 19 to 22 ).
[0189] Example 2-8: Confirmation of the inhibitory effect on cancer cell invasion
[0190] In the same manner as the experimental method described in Examples 1-8, the inhibitory effects of hCMAb45 and hCMAb96 on cancer cell invasiveness were confirmed.
[0191] As a result, the invasive ability of cancer cells was significantly reduced in the groups treated with hCMAb45 and hCMAb96 compared with the control IgG ( Figures 23 to 26 ).
[0192] Example 2-9: Confirmation of in vivo anticancer effect in pancreatic cancer animal model
[0193] Examples 2-7 and 2-8 confirmed in vitro the inhibitory effects of hCMAb45 and hCMAb96 humanized antibodies that specifically bind to CTHRC1 protein on cancer cell migration and invasion. Therefore, it was confirmed whether the anticancer effect was observed in vivo in the same manner. Specifically, a subcutaneous xenograft mouse model was prepared using the pancreatic cancer cell line BxPC-3 that overexpresses CTHRC1. 1×10 6 The cells were transplanted subcutaneously in the right leg of mice and after 6 days, selected cells developed into a 73 mm 3 Up to 77mm 3The mice of the tumor of 10mg / kg and it is divided into groups.Drug is injected into the tail vein, and the dosage of control IgG and hCMAb45 and hCMAb96 experimental groups is used twice a week with 10mg / kg, continues 4 weeks altogether, and uses caliper to measure the size of tumor twice a week.After antibody treatment, the experiment is terminated at the 28th day (treatment 8), and the tumor size is compared with respect to the tumor size of control IgG.
[0194] As a result, it was confirmed that the size of the tumor in the groups administered with hCMAb45 and hCMAb96 was reduced compared with the group administered with control IgG ( Fig. 27 ). In particular, it was confirmed that the group treated with hCMAb96 had a superior anticancer effect compared with the group treated with hCMAb45.
[0195] Through the above examples, the in vivo anti-cancer effects of hCMAb45 and hCMAb96 humanized antibodies that specifically bind to CTHRC1 were confirmed, and their potential as substances for delaying or inhibiting tumor growth was verified.
[0196] According to the foregoing, those skilled in the art to which the present invention belongs will be able to understand that, without changing the technical concept or basic features of the present invention, the present invention can be implemented in other specific forms. In this regard, the exemplary embodiments disclosed herein are for illustrative purposes only and should not be construed as limiting the scope of the present invention. The scope of the present invention is therefore indicated by the appended claims rather than by the foregoing description. All changes within the equivalent meaning and scope of the claims should be included within the scope of the present invention. <110> Prestige Biopharmaceuticals Pte Ltd <120> Novel CTHRC1 specific antibody and its use <130> OPA20050 <150> KR 10-2019-0070048 <151> 2019-06-13 <160> 28 <170> KoPatentIn 3.0 <210> 1 <211> 8 <212> PRT <213> Artificial sequence <220> <223> 4H5-VH-CDR1 <400> 1 Gly Tyr Ser Phe Thr Asp Tyr Ile 1 5 <210> 2 <211> 8 <212> PRT <213> Artificial sequence <220> <223> 4H5-VH-CDR2 <400> 2 Ile Asn Pro Tyr Tyr Gly Ser Thr 1 5 <210> 3 <211> 14 <212> PRT <213> Artificial sequence <220> <223> 4H5-VH-CDR3 <400> 3 Ala Arg Ser Gly Tyr Gly Tyr Asp Glu Ser Ala Met Asp Tyr 1 5 10 <210> 4 <211> 11 <212> PRT <213> Artificial sequence <220> <223> 4H5-VL-CDR1 <400> 4 Lys Ser Leu Leu Asn Ser Asp Gly Phe Thr Tyr 1 5 10 <210> 5 <211> 3 <212> PRT <213> Artificial sequence <220> <223> 4H5-VL-CDR2 <400> 5 Leu Val Ser 1 <210> 6 <211> 9 <212> PRT <213> Artificial sequence <220> <223> 4H5-VL-CDR3 <400> 6 Phe Gln Ser Asn Tyr Leu Pro Leu Thr 1 5 <210> 7 <211> 121 <212> PRT <213> Artificial sequence <220> <223> cCMAb45 - heavy chain <400> 7 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 20 25 30 Ile Met Leu Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asn Ile Asn Pro Tyr Tyr Gly Ser Thr Ser Tyr Asn Leu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Gly Tyr Gly Tyr Asp Glu Ser Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 8 <211> 363 <212> DNA <213> Artificial sequence <220> <223> cCMAb45 - heavy chain <400> 8 gaggtccagc tgcaacagtc tggacctgag ctggtgaagc ctggggcttc agtgaagata 60 tcctgcaagg cttctggtta ttcattcact gactacatca tgctctgggt gaagcagagc 120 catggaaaga gccttgagtg gattggaaat attaatcctt actatggtag tactagctac 180 aatctgaagt tcaagggcaa ggccacattg actgtagaca aatcttccag cacagcctac 240 atgcagctca acagtctgac atctgaggac tctgcagtct attactgtgc aagatcgggc 300 tatggttacg acgagagtgc tatggactac tggggtcaag gaacctcagt caccgtctcc 360 tca 363 <210> 9 <211> 112 <212> PRT <213> Artificial sequence <220> <223> cCMAb45 - light chain <400> 9 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Asn Ile Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Lys Ser Thr Lys Ser Leu Leu Asn Ser 20 25 30 Asp Gly Phe Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Ser 85 90 95 Asn Tyr Leu Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 10 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> cCMAb45 - light chain <400> 10 gatgttttga tgacccaaac tccactctct ctgcctgtca atattggaga tcaagcctct 60 atctcttgca agtctactaa gagtcttctg aatagtgatg gattcactta tttggactgg 120 tacctgcaga agccaggcca gtctccacag ctcctaatat atttggtttc taatcgattt 180 tctggagttc cagacaggtt cagtggcagt gggtcaggaa cagatttcac actcaagatc 240 agcagagtgg aggctgagga tttgggagtt tattattgct tccagagtaa ctatcttcct 300 ctcacgttcg gctcggggac aaagttggaa ataaaa 336 <210> 11 <211> 8 <212> PRT <213> Artificial sequence <220> <223> 9E6-VH-CDR1 <400> 11 Gly Tyr Thr Phe Thr Ser Tyr Trp 1 5 <210> 12 <211> 8 <212> PRT <213> Artificial sequence <220> <223> 9E6-VH-CDR2 <400> 12 Ile Tyr Pro Ser Ser Gly Thr Thr 1 5 <210> 13 <211> 5 <212> PRT <213> Artificial sequence <220> <223> 9E6-VH-CDR3 <400> 13 Thr Thr Glu Ser Tyr 1 5 <210> 14 <211> 6 <212> PRT <213> Artificial sequence <220> <223> 9E6-VL-CDR1 <400> 14 Gln Asn Ile Asn Val Trp 1 5 <210> 15 <211> 3 <212> PRT <213> Artificial sequence <220> <223> 9E6-VL-CDR2 <400> 15 Lys Ala Ser 1 <210> 16 <211> 9 <212> PRT <213> Artificial sequence <220> <223> 9E6-VL-CDR3 <400> 16 Gln Gln Gly Gln Ser Tyr Pro Leu Thr 1 5 <210> 17 <211> 112 <212> PRT <213> Artificial sequence <220> <223> cCMAb96-Heavy Chain <400> 17 Gln Val Gln Leu Gln Gln Pro Gly Ser Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Ser Gly Thr Thr Asn Tyr Asp Glu Lys Phe 50 55 60 Lys Asn Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Thr Thr Ala Tyr 65 70 75 80 Met His Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Glu Ser Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 100 105 110 <210> 18 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> cCMAb96 - heavy chain <400> 18 caggtccaac tgcagcagcc tgggtctgag ctggtgaggc ctggagcttc agtgaagctg 60 tcctgcaagg cttctggcta cacattcacc agctactgga tgcactgggt gaagcagagg 120 cctggacaag gccttgagtg gattggaaat atttatccta gtagtggtac tactaactac 180 gatgagaagt tcaagaacaa ggccacactg actgtagaca catcctccac cacagcctac 240 atgcacctca gcagcctgac atctgaggac tctgcggtct attactgtac aacagagtct 300 tactggggcc aaggcaccac tctcacagtc tcctca 336 <210> 19 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> cCMAb96 - light chain <400> 19 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Thr Ile Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp 20 25 30 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Asn Ile Pro Lys Leu Leu Ile 35 40 45 Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 20 <211> 321 <212> DNA <213> Artificial sequence <220> <223> cCMAb96 - light chain <400> 20 gacattgtga tgacccagtc tccatccagt ctgtctgcat cccttggaga cacaattacc 60 atcacttgcc atgccagtca gaacattaat gtttggttaa gctggtacca gcagaaacca 120 ggaaatattc ctaaactatt gatctataag gcttccaact tgcacacagg cgtcccatca 180 aggtttagtg gcagtggatc tggaacaggt ttcacattaa ccatcagcag cctgcagcct 240 gaagacattg ccacttacta ctgtcaacag ggtcaaagtt atcctctgac gttcggtgga 300 ggcaccaagc tggaaatcaa a 321 <210> 21 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> hCMAb45 - Heavy Chain <400> 21 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 20 25 30 Ile Ile Leu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Asn Pro Tyr Tyr Gly Ser Thr Val Tyr Gly Gln Lys Phe 50 55 60 Gln Gly Arg Leu Thr Ile Thr Ala Asp Gly Ser Met Ser Thr Ala Tyr 65 70 75 80 Methionine Glutamic acid Leucine Serine Serine Leucine Arginine Serine Glutamic acid Aspartic acid Threonine Alanine Valine Tyrosine Tyrosine Cysteine 85 90 95 Alanine Arginine Serine Glycine Tyrosine Glycine Tyrosine Aspartic acid Glutamic acid Serine Alanine Methionine Aspartic acid Tyrosine Tryptophan Glycine 100 105 110 Glutamine Glycine Threonine Leucine Valine Threonine Valine Serine Serine 115 120 <210> 22 <211> 363 <212> DNA <213> Artificial sequence <220> <223> hCMAb45 - heavy chain <400> 22 caggtgcagc tggtggagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60 tcctgcaagg cttctggtta ttcattcact gactacatca tattatgggt gcggcaggcg 120 cctggacaag ggcttgagtg gatgggagca attaatcctt actatggtag tactgtgtac 180 gggcagaagt tccagggcag actcaccatt accgcggacg ggtctatgag cacagcctac 240 atggagctga gcagcctgag atctgaggac actgcagtct attactgtgc aagatcgggc 300 tatggttacg acgagagtgc tatggactac tggggtcaag gaaccctagt caccgtctcc 360 tca 363 <210> 23 <211> 112 <212> PRT <213> Artificial sequence <220> <223> hCMAb45-light chain <400> twenty three Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Asn Ser 20 25 30 Asp Gly Phe Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Ser 85 90 95 Asn Tyr Leu Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> twenty four <211> 336 <212> DNA <213> Artificial sequence <220> <223> hCMAb45-light chain <400> twenty four gatattgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gccggcctct 60 gatattgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gccggcctct 60 atctcttgcc ggtctagtaa gagtcttctg aatagtgatg gattcactta tttggactgg 120 atctcttgcc ggtctagtaa gagtcttctg aatagtgatg gattcactta tttggactgg 120 tacctgcaga agccaggcca gtctccacag ctcctaatat atttggtttc taatcgattt 180 tacctgcaga agccaggcca gtctccacag ctcctaatat atttggtttc taatcgattt 180 tctggagttc cagacaggtt cagtggcagt gggtcaggaa cagatttcac actcaagatc 240 tctggagttc cagacaggtt cagtggcagt gggtcaggaa cagatttcac actcaagatc 240 agcagagtgg aggctgagga tgttggagtt tattattgct tccagagtaa ctatcttcct 300 agcagagtgg aggctgagga tgttggagtt tattattgct tccagagtaa ctatcttcct 300 ctcacgttcg gccaggggac aaagttggaa ataaaa 336 ctcacgttcg gccaggggac aaagttggaa ataaaa 336 <210> 25<210> 25 <211> 112<211> 112 <212> PRT<212> PRT <213> 人工序列<213> Artificial sequence <220><220> <223> hCMAb96-重链<223> hCMAb96 - Heavy chain <400> 25 <400> 25 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 35 40 45 Gly Tyr Ile Tyr Pro Ser Ser Gly Thr Thr Asn Tyr Asn Gln Lys Phe Gly Tyr Ile Tyr Pro Ser Ser Gly Thr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Pro Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Glu Ser Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 26 <211> 336 <212> DNA <213> Artificial sequence <220> <223> hCMAb96 - heavy chain <400> 26 caggtccaac tggtacagtc tggggctgaa gtgaagaagc ctggggcttc agtgaaggtc 60 tcctgtaagg cttctggcta cacattcacc agctactgga tgcactgggt ccgtcaagct 120 ccgggacaag ggctggagtg gattggatat atttatccta gtagtggtac tactaactac 180 aaccaaaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac 240 atggagctga gccccctgag atctgaggac acagcggtct attactgtac aacagagtct 300 tactggggcc agggaaccac tgtcaccgtc tcctca 336 <210> 27 <211> 107 <212> PRT <213> Artificial sequence <220> <223> hCMAb96-light chain <400> 27 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Thr Ile Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Lys Ala Ser Asn Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 28 <211> 321 <212> DNA <213> Artificial sequence <220> <223> hCMAb96-light chain <400> 28 gacattcaga tgacccagtc tccatccagt ctgtctgcat cccttggaga cacaattacc 60 atcacttgcc atgccagtca gaacattaat gtttggttag cctggtatca gcagaaacca 120 gggaaagccc ctaaactatt gatctataag gcttccaact tgcacagtgg cgtcccatca 180 aggtttagtg gcagtggatc tggaacagat ttcactctca ccatcagcag cctgcagcct 240 gaagacattg ccacttacta ctgtcaacag ggtcaaagtt atcctctgac gttcggccag 300 gggaccaagg tggaaatcaa a 321
Claims
1. An antibody that specifically binds to a collagen triple helix repeat-containing sequence 1 (CTHRC1) protein, comprising: (a) a heavy chain variable region comprising a heavy chain CDR1 consisting of SEQ ID NO: 11, a heavy chain CDR2 consisting of SEQ ID NO: 12, and a heavy chain CDR3 consisting of SEQ ID NO: 13; and (b) a light chain variable region comprising a light chain CDR1 consisting of SEQ ID NO:14, a light chain CDR2 consisting of SEQ ID NO:15, and a light chain CDR3 consisting of SEQ ID NO:
16.
2. The antibody of claim 1, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 17 or 25; and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 19 or 27.
3. A polynucleotide encoding the antibody according to claim 1 or 2. An expression vector comprising the polynucleotide according to claim 3 . A host cell comprising the expression vector according to claim 4 .
6. A pharmaceutical composition for preventing or treating cancer, comprising the antibody according to claim 1 or 2.
7. The composition of claim 6, wherein the cancer is selected from the group consisting of pancreatic cancer, ovarian cancer, breast cancer, melanoma, liver cancer, gastric cancer, lung cancer, colorectal cancer, oral cancer, cervical cancer, and bladder cancer.
8. Use of the antibody according to claim 1 or 2 for preparing a composition for diagnosing cancer in a biological sample isolated from a subject suspected of having cancer.
9. Use of the antibody according to claim 1 or 2 for preparing a composition for predicting cancer prognosis in a biological sample isolated from a subject suffering from cancer.
10. A composition for diagnosing cancer or predicting the prognosis of cancer, comprising the antibody according to claim 1 or 2.
11. A kit for diagnosing cancer or predicting the prognosis of cancer, comprising the composition according to claim 10.
12. A kit for detecting CTHRC1, comprising the antibody according to claim 1 or 2.
13. The kit of claim 12, wherein the kit is in the form of an ELISA.
14. The kit of claim 13, wherein the antibody is a capture antibody.
15. The kit of claim 13, wherein the ELISA is an indirect ELISA comprising: (i) a polyclonal antibody that binds to CTHRC1; (ii) a capture antibody in the form of an antibody as claimed in claim 1 or 2; as well as (iii) Antibody that binds to the detection marker IgG Fc.
16. Use of the antibody according to claim 1 or 2 for preparing a composition for detecting CTHRC1 protein in a sample.
